Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Allogeneic STC in Cutaneous T-cell Lymphoma

Studying remission in common variants

Publish date:: October 7, 2015

Allogeneic stem cell transplantation (SCT) may result in long-term remissions in a subset of patients with advanced cutaneous T-cell lymphoma (CTCL), according to a study of 47 patients with CTCL who underwent allogeneic SCT. Researchers found:

• Overall survival (OS) at 4 years was estimated at 51%

• Progression-free survival (PFS) at 4 years was estimated at 26%.

• No statistical difference was seen in OS in patients who had the common variants Mycosis fungoides (MF) or leukemic Sézary syndrome (SS) nor in patients who had MF with large cell transformation or SS with large cell transformation.

• PFS at 4 years was superior in patients who had SS (52.4%) vs those who did not (9.9%).

• Cumulative incidences of grade 2 to 4 acute graft versus host disease (GVHD) and chronic GVHD were 40% and 28%, respectively.

• Cumulative nonrelapse mortality rate was 16.7% at 2 years.

Citation: Hosing C, Bassett R, Dabaja B, et al. Allogeneic stem cell transplantation in patients with cutaneous lymphoma: Updated results from a single institution. [Published online ahead of print September 28, 2015]. Ann Oncol. doi: 10.1093/annonc/mdv473.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in T Cell Lymphomas

Phase 1 study shows feasibility, safety, efficacy of STAR T cells for ALL,

Duvelisib response rate encouraging in phase 2 PRIMO trial of patients with r/r PTCL,

Allogeneic transplant leads to durable remissions in T-cell lymphomas,

Survey quantifies COVID-19’s impact on oncology,

Lymphocyte, monocyte data can predict treatment response in follicular lymphoma,